Articles tagged with Breast Cancer
Women with cosmetic breast implants are at a higher risk of being diagnosed with late-stage breast cancer and having poorer survival rates than those without implants. Researchers found a 26% increased risk of delayed diagnosis and a 38% greater risk of death from breast cancer among women with implants.
Scientists at the University of Michigan have decoded the molecular signals that enable cancer cells to spread throughout the body. By understanding how tumor cells recruit healing cells, researchers can now develop drugs to block these messages and prevent metastasis.
A new study by the University of Leicester found that women from deprived areas have poorer breast cancer survival rates due to late-stage diagnoses. The research suggests that prioritizing early detection in these areas can significantly improve survival chances and reduce deaths.
A big data analysis identified 37 RNA molecules that may predict survival in breast cancer patients with the most common form of invasive ductal carcinoma. The study found a concise RNA signature associated with patient outcome, including early-stage tumors and those with clinical and molecular subclasses.
A comprehensive analysis of 83,399 women found SERMs significantly reduce ER-positive breast cancer incidence by 38%. The study also showed increased thromboembolic events with all SERMs except tamoxifen.
Research found that pregnancy decreases breast cancer risk in humans and mice by down-regulating genes involved in growth factors and immune system. The study also revealed a permanent alteration in mammary tissue stem cells, preventing runaway cell growth characteristic of cancer.
A large-scale trial found that integrated 2D and 3D screening detected more cancers and reduced false positives compared to 2D screening alone. The study showed a rate of 5.3 cancers per 1,000 screens detected by 2D screening versus 8.1 with combined 2D and 3D screening.
A study at Lund University found that drinking two or more cups of coffee daily may reduce the risk of breast cancer recurrence in patients taking Tamoxifen. Caffeine has been shown to hamper cancer cell growth and activate Tamoxifen, making it more efficient.
A prospective study by Brigham and Women's Hospital researchers observed an association between a history of non-melanoma skin cancer and increased risk of breast, lung, and melanoma cancers. The study found that people with non-melanoma skin cancer had a modestly increased risk of getting these cancers in the future.
New research reveals microwave tomography can effectively monitor breast cancer treatment, identifying shrinking tumors and guiding timely treatment changes. This non-invasive imaging technique is low-cost, easy to repeat, and unaffected by factors like body mass index or age.
A new pathway has been identified that enhances tamoxifen's effectiveness in treating basal-like breast cancer, a subtype resistant to treatment. The discovery involves targeting Cdc42 protein to restore normal function of c-Cbl and improve cancer cell death.
Researchers at Karolinska Institutet developed a method to assess tamoxifen's effect on breast cancer, using mammograms. Women showing a 20% reduction in breast density have a 50% reduced risk of dying from breast cancer over 15 years.
Researchers discovered metastasis stem cells in the blood of breast cancer patients, characterized by specific surface molecules CD44, CD47, and MET. These cells are associated with a poorer prognosis and may serve as a promising biomarker for disease progression.
Researchers are working on a technique that can help identify and treat cancer tumors using manganese-enhanced magnetic resonance imaging (MEMRI). The goal is to guide and individualize treatment based on the presence of specific calcium channels in tumors.
Researchers at Ohio State University Comprehensive Cancer Center found that AS1411 reduces cancer aggressiveness by inhibiting microRNA maturation, while restoring sensitivity to fulvestrant in resistant cells. The study suggests a new strategy for treating breast cancer.
A commonly used drug, ACE inhibitor, can limit radiation damage to the lungs and heart in cancer patients. The study found that this treatment improved the heart's function and decreased fibrosis in the heart after irradiation.
A randomised trial found that intensity modulated radiotherapy (IMRT) significantly reduced skin telangiectasia and improved cosmetic effect in patients with early breast cancer. IMRT delivers an even dose of radiation, reducing undesirable side-effects.
A study found that low-dose aspirin slowed the growth of two breast cancer lines in lab tests and reduced tumor growth in mice. The compound also inhibited tumor cells from spreading and enhanced the effect of tamoxifen, a common drug therapy for hormone-receptor positive breast cancer.
A new UCLA study finds a significant correlation between poorer performance on neuropsychological tests and memory complaints in post-treatment, early-stage breast cancer patients. The research suggests that 'chemo brain' may involve neurophysiological changes associated with chemotherapy and radiation treatment.
A novel monoclonal antibody targeting SFRP2 has been shown to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. The antibody is the first therapeutic discovered that targets SFRP2, a protein linked to angiogenesis and cancer progression.
A study from Yale University found that two views are better than one in 3D breast screening to ensure optimal cancer detection. The CC view achieves better compression and shows lesions clearer due to its ability to compress the breast tissue.
A new study suggests that tomosynthesis increases breast cancer detection rates by 11%, particularly benefiting women with dense breasts. The technology's improved performance in dense breast tissue was attributed to its ability to detect invasive and intraductal cancers more accurately.
Research found that low-vitamin D season can reduce breast cancer treatment effectiveness by up to 30%. The study identifies seasonal and genetic factors affecting tamoxifen metabolism.
A new study reveals that breast ultrasound screening after mammography can detect an additional 3.4 cancers per thousand women screened in those with greater than 50% breast density. The detection rate is comparable to that of screening mammography for women with less dense breasts.
Researchers identified three BRCA1 gene variants as pathogenic, increasing breast and ovarian cancer risk. These findings will improve genetic counseling and allow for personalized cancer assessment.
Dr. Susan E. Clare's research aims to deliver chemotherapy directly to brain metastases using immune cells and nanoparticles, targeting HER2 positive and triple negative breast cancers. The system uses nanoshells coated with gold to release drugs at will in the appropriate spot in the brain.
A study by researchers at Fred Hutchinson Cancer Center found that fewer than 8% of breast cancer survivors met national exercise guidelines over a 10-year period. Despite benefits such as reduced mortality and improved quality of life, many survivors struggle to maintain adequate physical activity.
Researchers at Columbia University developed a new computational model that uses gene signatures to predict breast cancer survival with high accuracy. The model, which won a crowd-sourced challenge, has the potential to improve diagnostic and prognostic products for multiple types of cancer.
The DREAM Breast Cancer Prognosis Challenge successfully predicted better breast cancer progression than existing models, using genomic and clinical information from 2000 women. The winning team, Attractor Metagenes, developed a model based on 'attractor metagenes,' gene signatures that behave similarly in multiple cancer types.
Researchers at Lund University have discovered that exosome molecular profiles reflect the aggressiveness of brain tumours, offering a new approach for diagnosis and treatment. The study's findings suggest that exosomes could serve as biomarkers to guide patient care and monitor treatment response.
High levels of kisspeptins in aggressive breast cancers increase tumor grade and metastatic potential, according to Western University research. The study suggests that estrogen receptor status may play a role in kisspeptin's unusual behavior, making it a potential diagnostic biomarker for more aggressive breast cancer.
The study found that women with more advanced breast cancer at diagnosis, higher body mass index, and more positive lymph nodes were at increased risk of developing lymphedema. Genetic markers associated with the development of lymphedema in breast cancer survivors were also identified.
Researchers at UCLA have developed a potentially more effective treatment for triple-negative breast cancer (TNBC) using nanoscale, diamond-like particles called nanodiamonds. The new compound has been shown to decrease tumor growth and eliminate side effects of cancer treatment in mice.
The American College of Physicians recommends high-risk women receive preventive drug therapy to reduce risk of primary breast cancer. CT scans can also be used to screen for osteoporosis at lower costs without additional radiation exposure. However, using computer-aided detection in mammography increases diagnosis of early stage cance...
Researchers at Massachusetts General Hospital identified a genetic signature associated with the risk of tumor recurrence or spread in men surgically treated for prostate cancer. The 32-gene index proved to be the most accurate method, predicting actual incidence of tumor recurrence (47%) and metastasis (14%) among high-risk patients.
Researchers at IRCM identified the DOCK1 protein as a key regulator of metastasis in breast cancer. The study found that eliminating DOCK1 in mice resulted in a significant decrease in lung metastases and tumor growth.
Tomosynthesis surpasses 2D mammography in detecting infiltrating ductal carcinoma, particularly in women at increased risk of breast cancer. The study found that tomosynthesis improved visibility in 41% of cases and identified cancers only visible on tomosynthesis.
A new breast imaging algorithm is being implemented in Uganda to diagnose and treat women with palpable breast masses. The program combines a unique diagnostic algorithm with targeted community outreach to combat myths surrounding cancer, aiming for early diagnosis and effective care.
Gabriel Hortobagyi, a renowned breast cancer researcher, is being recognized for his contributions to advancing minority investigators in cancer research. He has developed groundbreaking therapies and treatment regimens that have become standard practices for managing breast cancer.
Breast cancers with high androgen receptor (AR) levels are more likely to relapse after estrogen-targeting therapies. Anti-androgen therapy shows promising responses in cell lines and preclinical models, offering a new potential target for breast cancer treatment.
Researchers found that omega-3 fatty acids and their metabolites slow or stop the proliferation of triple-negative breast cancer cells, reducing growth by up to 90 percent. The effect was stronger in triple-negative cell lines, with reduced motility and apoptosis rates.
A new study found that one-quarter of women who need hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course. Side effects were cited as the most common reason for skipping treatment.
A new study by Fox Chase researchers finds that heterogeneity is prevalent even in early-stage ductal carcinoma in situ (DCIS) breast cancer, making it challenging for pathologists to accurately diagnose and treat the disease. The results suggest that a multiple-target approach may be necessary to effectively combat breast cancer.
Researchers found that excess estrogen levels during pregnancy can silence the BRCA1 tumor suppressor gene, increasing breast cancer risk in daughters. Additionally, molecular abnormalities in the unfolded protein response pathway were also found to contribute to breast cancer risk.
Scientists at Fox Chase Cancer Center have identified several dozen transcripts known as lincRNAs that are dysregulated in breast cancer. The study found that these lincRNAs are differentially regulated within breast cancer cell lines, indicating their potential role in tumorigenesis or regulation of other cancers.
A study at Capital Breast Cancer Center (CBCC) found that low-income and minority women screened for breast cancer had a high rate of medical follow-up after a positive mammogram. The researchers credit CBCC patient navigators with playing a key role in ensuring the high follow-up rates.
A new study published in the Journal of Clinical Oncology found that alcohol consumption before and after diagnosis has no impact on breast cancer survival. However, moderate drinkers may have a reduced risk of dying from cardiovascular disease, with moderate wine consumption associated with a lower risk.
A study found that only 53% of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation received a recommendation for genetic testing. Women who were older, had lower income, and were employed were less likely to receive the recommendation.
Research shows that inhibiting autophagy in breast cancers dependent on it may be enough alone to kill the disease. Chloroquine, an anti-malaria drug, has been found to inhibit autophagy and is being tested as a potential treatment for certain breast cancer subtypes.
A subset of breast cancer patients with HER-2 positive tumors may benefit from a combination of targeted treatments that avoid chemotherapy. The study, published in the Journal of Clinical Oncology, shows high efficacy in eradicating tumors and offers a groundbreaking approach to treatment without significant side effects.
Researchers at Moffitt Cancer Center found that microRNA-155 overexpression promotes new blood vessel growth, tumor inflammation, and metastasis in breast cancer. Controlling miR-155 expression could inhibit malignant growth, providing a new avenue of treatment.
The CTC-iChip system rapidly produces a purified solution of tumor cells for pathological and molecular analysis. This technology enables the analysis of single metastatic cells, providing insights into cancer evolution and metastasis.
Researchers at Princess Margaret Cancer Centre identify Notch signalling pathway as key driver of resistance to hormone therapies in ER-positive breast cancer cells. A companion prognostic test is proposed to predict tumour response to new therapy.
A study published in the Journal of the National Cancer Institute found that estrogen plus progestin use is associated with an increased risk of breast cancer incidence. However, survival after diagnosis did not differ between users and non-users, suggesting higher mortality rates among hormone therapy users.
A recent study published in the Journal of the National Cancer Institute found that estrogen plus progestin use is associated with an increased risk of breast cancer. The study suggests that mortality from breast cancer may be higher for women using this combined hormonal therapy.
An international study has identified up to 80 new regions of the genome associated with increased susceptibility to breast, prostate, and ovarian cancers. Researchers have also discovered a total of 41 new genes or regions that may contribute to the development of breast cancer.
Researchers at Mayo Clinic Cancer Center have identified new DNA sequences linked to an increased risk of developing breast and ovarian cancers. The findings, published in three studies, will help improve risk models and support new prevention strategies for these diseases.
Researchers identified a specific cell membrane protein blocking cell death in hormone-therapy-related breast cancers, which could be targeted by new therapies. Progestin, a synthetic hormone used in hormone replacement therapy, affects the protein's activity and increases cancer risk.
A large-scale research study has identified over 80 genetic 'spelling mistakes' linked to an increased risk of breast, prostate, and ovarian cancers. The study found that these alterations can be described as single nucleotide polymorphisms (SNPs), which are common in the DNA of patients with cancer.
A Quebec researcher has identified 49 new genetic variations linked to breast cancer, almost tripling the known number of risk factors. The discovery was made as part of a massive international study involving over 200,000 participants and will help predict breast cancer risk with greater accuracy.